Indigotindisulfonate sodium
Bludigo (indigotindisulfonate sodium) is a small molecule pharmaceutical. Indigotindisulfonate sodium was first approved as Bludigo on 2022-07-08.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Bludigo
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Indigotindisulfonate sodium
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| BLUDIGO | Provepharm | N-216264 RX | 2022-07-08 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| bludigo | New Drug Application | 2022-11-07 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
INDIGOTINDISULFONATE SODIUM, BLUDIGO, PROVEPHARM SAS | |||
| 2027-07-08 | NCE | ||
HCPCS
No data
Clinical
Clinical Trials
32 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Promyelocytic leukemia acute | D015473 | C92.4 | — | — | 2 | — | — | 2 | |
| Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Psoriasis | D011565 | EFO_0000676 | L40 | — | 3 | — | — | — | 3 |
| Atopic dermatitis | D003876 | EFO_0000274 | L20 | — | 1 | — | — | — | 1 |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | 1 | 1 | — | — | — | 1 |
| Anus neoplasms | D001005 | EFO_0003835 | C21 | — | 1 | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Rectal neoplasms | D012004 | — | — | — | — | 1 | 1 | ||
| Colonic neoplasms | D003110 | C18 | — | — | — | — | 1 | 1 | |
| Colonoscopy | D003113 | — | — | — | — | 1 | 1 | ||
| Inflammatory bowel diseases | D015212 | EFO_0003767 | — | — | — | — | 1 | 1 | |
| Ulcerative colitis | D003093 | EFO_0000729 | K51 | — | — | — | — | 1 | 1 |
| Lymphocytic colitis | D046730 | EFO_1001294 | K52.832 | — | — | — | — | 1 | 1 |
| Collagenous colitis | D046729 | EFO_1001293 | K52.831 | — | — | — | — | 1 | 1 |
| Venous thrombosis | D020246 | HP_0004936 | I82.40 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | INDIGOTINDISULFONATE SODIUM |
| INN | — |
| Description | Indigo carmine, or 5,5′-indigodisulfonic acid sodium salt, is an organic salt derived from indigo by aromatic sulfonation, which renders the compound soluble in water. It is approved for use as a food colorant in the U.S and E.U. to produce a blue color. It has the E number E132. It is also a pH indicator.
|
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | O=C1/C(=C2\Nc3ccc(S(=O)(=O)[O-])cc3C2=O)Nc2ccc(S(=O)(=O)[O-])cc21.[Na+].[Na+] |
Identifiers
| PDB | — |
| CAS-ID | 860-22-0 |
| RxCUI | 227312 |
| ChEMBL ID | CHEMBL2105023 |
| ChEBI ID | 31695 |
| PubChem CID | 5284351 |
| DrugBank | DB11577 |
| UNII ID | — |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 13 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more